Radiomics model based on contrast-enhanced computed tomography imaging for early recurrence monitoring after radical resection of AFP-negative hepatocellular carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Carcinoma, Hepatocellular*/surgery ; Carcinoma, Hepatocellular*/diagnostic imaging ; Carcinoma, Hepatocellular*/pathology ; Liver Neoplasms*/surgery ; Liver Neoplasms*/diagnostic imaging ; Liver Neoplasms*/pathology ; alpha-Fetoproteins*/metabolism ; alpha-Fetoproteins*/analysis ; Neoplasm Recurrence, Local*/diagnostic imaging ; Tomography, X-Ray Computed*/methods ; Contrast Media*; Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Adult ; Hepatectomy ; Prognosis ; Radiomics
    • Abstract:
      Background: Although radical surgical resection is the most effective treatment for hepatocellular carcinoma (HCC), the high rate of postoperative recurrence remains a major challenge, especially in patients with alpha-fetoprotein (AFP)-negative HCC who lack effective biomarkers for postoperative recurrence surveillance. Emerging radiomics can reveal subtle structural changes in tumors by analyzing preoperative contrast-enhanced computer tomography (CECT) imaging data and may provide new ways to predict early recurrence (recurrence within 2 years) in AFP-negative HCC. In this study, we propose to develop a radiomics model based on preoperative CECT to predict the risk of early recurrence after surgery in AFP-negative HCC.
      Patients and Methods: Patients with AFP-negative HCC who underwent radical resection were included in this study. A computerized tool was used to extract radiomic features from the tumor region of interest (ROI), select the best radiographic features associated with patient's postoperative recurrence, and use them to construct the radiomics score (RadScore), which was then combined with clinical and follow-up information to comprehensively evaluate the reliability of the model.
      Results: A total of 148 patients with AFP-negative HCC were enrolled in this study, and 1,977 radiographic features were extracted from CECT, 2 of which were the features most associated with recurrence in AFP-negative HCC. They had good predictive ability in both the training and validation cohorts, with an area under the ROC curve (AUC) of 0.709 and 0.764, respectively. Tumor number, microvascular invasion (MVI), AGPR and radiomic features were independent risk factors for early postoperative recurrence in patients with AFP-negative HCC. The AUCs of the integrated model in the training and validation cohorts were 0.793 and 0.791, respectively. The integrated model possessed the clinical value of predicting early postoperative recurrence in patients with AFP-negative HCC according to decision curve analysis, which allowed the classification of patients into subgroups of high-risk and low-risk for early recurrence.
      Conclusion: The nomogram constructed by combining clinical and imaging features has favorable performance in predicting the probability of early postoperative recurrence in AFP-negative HCC patients, which can help optimize the therapeutic decision-making and prognostic assessment of AFP-negative HCC patients.
      (© 2024. The Author(s).)
    • References:
      Cancer Imaging. 2019 Feb 27;19(1):11. (PMID: 30813956)
      World J Gastroenterol. 2023 Jul 14;29(26):4186-4199. (PMID: 37475840)
      World J Gastroenterol. 2015 Jan 28;21(4):1207-15. (PMID: 25632194)
      Cancer Med. 2020 Apr;9(8):2791-2802. (PMID: 32096346)
      Semin Liver Dis. 1999;19(3):329-38. (PMID: 10518312)
      Nat Rev Clin Oncol. 2024 Apr;21(4):294-311. (PMID: 38424197)
      Cancer Metastasis Rev. 2023 Sep;42(3):629-652. (PMID: 36729264)
      J Hepatocell Carcinoma. 2023 Feb 08;10:193-202. (PMID: 36789253)
      Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. (PMID: 31439937)
      World J Gastroenterol. 2022 Jul 21;28(27):3503-3513. (PMID: 36158257)
      Clin Cancer Res. 2015 Jan 15;21(2):249-57. (PMID: 25421725)
      J Hepatol. 2001 Sep;35(3):421-30. (PMID: 11592607)
      J Hematol Oncol. 2020 Jan 8;13(1):5. (PMID: 31915027)
      Radiology. 2016 Feb;278(2):563-77. (PMID: 26579733)
      Hepatobiliary Surg Nutr. 2023 Apr 10;12(2):155-168. (PMID: 37124678)
      Radiol Med. 2023 Mar;128(3):261-273. (PMID: 36763316)
      J Hepatocell Carcinoma. 2022 Mar 20;9:189-201. (PMID: 35340666)
      Ann Surg Oncol. 2022 Feb 22;:. (PMID: 35192156)
      Int J Oncol. 2015 Aug;47(2):543-54. (PMID: 26058824)
      Eur Radiol. 2009 Oct;19 Suppl 5:S975-89. (PMID: 19851766)
      N Engl J Med. 2019 Apr 11;380(15):1450-1462. (PMID: 30970190)
      J Pathol. 2003 Mar;199(3):345-53. (PMID: 12579536)
      Ann Surg. 2007 Jun;245(6):909-22. (PMID: 17522517)
      Radiology. 2023 May;307(4):e222729. (PMID: 37097141)
      Radiology. 2020 Mar;294(3):568-579. (PMID: 31934830)
      Eur J Cancer. 2012 Mar;48(4):441-6. (PMID: 22257792)
      Hepatology. 2002 Apr;35(4):853-60. (PMID: 11915031)
      Gastroenterology. 2011 Mar;140(3):1071-83. (PMID: 21147110)
      Front Oncol. 2022 Nov 10;12:1013770. (PMID: 36439458)
      J Hepatol. 2017 Mar;66(3):552-559. (PMID: 27899297)
      Int J Colorectal Dis. 2016 Nov;31(11):1739-1749. (PMID: 27682648)
      Cell. 2021 Jan 21;184(2):404-421.e16. (PMID: 33357445)
      Gastroenterology. 1989 Feb;96(2 Pt 1):527-9. (PMID: 2535996)
      J Hepatocell Carcinoma. 2021 Feb 09;8:23-33. (PMID: 33604313)
      Radiology. 2023 Feb;306(2):e220531. (PMID: 36219111)
      Hepatology. 2018 Jan;67(1):358-380. (PMID: 28130846)
      Gastroenterology. 2011 May;140(5):1501-12.e2. (PMID: 21320499)
      J Hepatol. 2012 Feb;56(2):412-8. (PMID: 21756858)
      Nat Biotechnol. 2007 Jun;25(6):675-80. (PMID: 17515910)
      J Transl Med. 2023 Aug 4;21(1):526. (PMID: 37542324)
      Radiology. 2023 May;307(3):e221429. (PMID: 37014244)
    • Grant Information:
      81773148 National Natural Science Foundation of China; GKE-KF202101 Opening Project of Key laboratory of High-Incidence-Tumor Prevention & Treatment(Guangxi Medical University), Ministry of Education
    • Contributed Indexing:
      Keywords: AFP-negative; Contrast-enhanced computed tomography; Hepatocellular carcinoma; Radiomics; Recurrence prediction
    • Accession Number:
      0 (alpha-Fetoproteins)
      0 (Contrast Media)
    • Publication Date:
      Date Created: 20240607 Date Completed: 20240607 Latest Revision: 20240610
    • Publication Date:
      20240610
    • Accession Number:
      PMC11157869
    • Accession Number:
      10.1186/s12885-024-12436-x
    • Accession Number:
      38849749